QCM Cayman’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

QCM Cayman’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,181	Closed	-$220K	–	121
2018 Q4	$220K	Buy	+2,181	New	+$226K	0.9%	55
2017 Q3	–	Sell	-1,955	Closed	-$237K	–	240
2017 Q2	$237K	Buy	+1,955	New	+$226K	0.54%	95
2016 Q2	–	Sell	-1,933	Closed	-$248K	–	371
2016 Q1	$248K	Buy	+1,933	New	+$228K	0.17%	110

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

QCM Cayman's ICPT Position: Q1 2019 in Review

QCM Cayman sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2019, closing a stake of 2,181 shares — an estimated $220K sold.

QCM Cayman first reported a position in ICPT in Q1 2016 and held it in 3 quarters. The position peaked at $248K in Q1 2016. 202 funds tracked by Wall St. Rank hold ICPT as of Q1 2019.

QCM Cayman reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
QCM Cayman sold 2,181 Intercept Pharmaceuticals, Inc. shares in Q1 2019, an estimated $220K.
QCM Cayman first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2016 and held it in 3 quarters.
QCM Cayman's Intercept Pharmaceuticals, Inc. position peaked at $248K in Q1 2016.
202 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2019.

Based on QCM Cayman's 13F filing for Q1 2019, filed 13 May 2019.